Hematology-Oncology
Midterm Cognitive Outcomes After CAR T-Cell Therapy in CNS Lymphoma Patients: Encouraging Evidence Beyond Acute Neurotoxicity
This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.
